Astra Breast Cancer Pill Slows Disease by Over Six Months (1)

AstraZeneca Plc’s experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors’ attention.

Camizestrant, in combination with other cancer medicines, helped patients with a specific type of breast cancer to live for a median of 16 months without their cancer progressing, compared with 9.2 months for those taking the current standard treatment.

Astra hopes the study data, presented at the American Society of Clinical Oncology’s annual meeting in Chicago, will help establish a new treatment strategy for some breast cancer patients.

The drugmaker’s shares ...